Filing Details

Accession Number:
0001437749-14-011463
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-06-18 17:46:11
Reporting Period:
2014-06-16
Filing Date:
2014-06-18
Accepted Time:
2014-06-18 16:46:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1484478 Furiex Pharmaceuticals Inc. FURX Pharmaceutical Preparations (2834) 271197863
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1492646 Frances Gail Mcintyre C/O Furiex Pharmaceuticals, Inc.,
3900 Paramount Parkway, Suite 150
Morrisville NC 27560
Senior Vice President-Research No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-06-16 3,804 $105.00 24,318 No 4 S Direct
Common Stock Acquisiton 2014-06-16 32,928 $9.11 57,246 No 4 M Direct
Common Stock Disposition 2014-06-16 32,928 $105.00 24,318 No 4 S Direct
Common Stock Acquisiton 2014-06-16 26,000 $15.00 50,318 No 4 M Direct
Common Stock Disposition 2014-06-16 26,000 $105.01 24,318 No 4 S Direct
Common Stock Acquisiton 2014-06-16 3,717 $13.16 28,035 No 4 M Direct
Common Stock Disposition 2014-06-16 3,717 $105.05 24,318 No 4 S Direct
Common Stock Acquisiton 2014-06-17 8,008 $13.16 32,326 No 4 M Direct
Common Stock Disposition 2014-06-17 8,008 $105.00 24,318 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (to buy) Disposition 2014-06-16 32,928 $0.00 32,928 $9.11
Common Stock Stock Options (to buy) Disposition 2014-06-16 26,000 $0.00 26,000 $15.00
Common Stock Stock Options (to buy) Disposition 2014-06-16 3,717 $0.00 3,717 $13.16
Common Stock Stock Options (to buy) Disposition 2014-06-17 8,008 $0.00 8,008 $13.16
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
22,763 2020-06-17 No 4 M Direct
0 2021-05-09 No 4 M Direct
34,227 2021-10-03 No 4 M Direct
26,219 2021-10-03 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Options (to buy) $17.80 2022-02-24 10,368 10,368 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2022-02-24 10,368 10,368 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.03, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.03 to $105.08, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
  4. All options became 100% vested on June 11, 2014 in connection with the Agreement and Plan of Merger dated as of April 27, 2014 by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc.